[rVSVΔG-ZEBOV] Ebola Prevention Vaccine Evaluation in Sierra Leone

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 12 Oct 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RVSV-S-GP/VP40 vaccine (Primary)
Indications Ebola virus infections
Focus Adverse reactions
Acronyms STRIVE

Most Recent Events

05 Oct 2022 Results of post-hoc pooled analysis of 3 studies(PREVAIL:NCT02344407; FLW: PACTR201503001057193; STRIVE:NCT02378753) published in the Vaccine
25 Oct 2020 Results of post-hoc pooled analysis of 3 studies (Guinea (FLW), Sierra Leone (STRIVE), and Liberia (PREVAIL)), presented at the IDWeek 2020.
05 Apr 2017 Status changed from active, no longer recruiting to completed.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight